Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Additional Information (Detail)

v3.19.1
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Jan. 01, 2019
Nov. 14, 2018
Mar. 31, 2015
Accounting Policies [Line Items]          
Percentage of tax benefit likely of being realized 50.00%        
Restricted Cash and Cash Equivalents $ 16,100 $ 16,000      
Allowance for Doubtful Accounts Receivable $ 3,100 1,300      
Debt Instrument, Interest Rate, Stated Percentage 17.00%        
Pledged Assets Separately Reported, Loans Pledged as Collateral, at Fair Value $ 1,200 1,100      
Time Deposits, at Carrying Value $ 27,600 $ 50,000      
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 35.00%      
Revenue from Contract with Customer, Including Assessed Tax $ 23,376 $ 15,520      
Notes Payable 79,503 62,499     $ 10,000
Maximum [Member]          
Accounting Policies [Line Items]          
Operating Lease, Liability     $ 24,900    
Operating Lease, Right-of-Use Asset     22,000    
Minimum [Member]          
Accounting Policies [Line Items]          
Operating Lease, Liability     27,500    
Operating Lease, Right-of-Use Asset     $ 24,600    
Held-to-maturity Securities [Member]          
Accounting Policies [Line Items]          
Time Deposits, at Carrying Value   36,000   $ 17,600  
Cash and Cash Equivalents [Member]          
Accounting Policies [Line Items]          
Time Deposits, at Carrying Value   14,000   $ 10,000  
Return Reserve [Member]          
Accounting Policies [Line Items]          
Revenue from Contract with Customer, Including Assessed Tax 2,400 1,200      
Hercules Note Payble [Member]          
Accounting Policies [Line Items]          
Restricted Cash and Cash Equivalents 14,900 $ 14,900      
Helocyte Inc [Member]          
Accounting Policies [Line Items]          
Notes Payable $ 4,400